International Mammalian Genome Society

logo18th International Mouse Genome Conference

17-22 October 2004, Seattle, USA


POSTER 191 - EMERILLON THERAPEUTICS’ ACB/BCA RECOMBINANT CONGENIC STRAINS: GENE MAPPING AND DISSECTION OF COMPLEX TRAITS.

Fortin A, Skamene E

Emerillon Therapeutics Inc., Montreal, Canada

The AcB/BcA gene discovery platform is a series of 36 Recombinant Congenic Strains, which were produced from the second backcross generation of the two progenitor mouse strains A/J and C57BL/6J. Each individual inbred RCS carries 12.5% of the donor genome in 87.5% of the background genome.  As the two parental inbred strains A/J and C57BL/6J are known to vary in the expression of resistance and susceptibility to a considerable number of mouse models of important human diseases, the AcB/BcA RCS platform represents a valuable and versatile genetic tool to study many different phenotypes.

The AcB/BcA RCS platform was used by our group and others to study a series of complex phenotypes including malaria infection, lipid metabolism, nociception and osteoporosis. In each case, the survey of the RC strain panel led to the identification of informative “pheno-deviant” strains, which exhibit a phenotype significantly different from the background progenitor. These strains were selected for further gene identification studies, including linkage mapping in secondary crosses and gene expression analyses in targeted organs. The development of a central database integrating all phenotypic, genetic and expression information produced from the AcB/BcA RCS platform is currently ongoing. This bioinformatics tool, which is linked to public databases, can be used to examine phenotypic data, look for correlation between phenotypes or sub-phenotypes, and investigate candidate genes underlying QTLs.

[an error occurred while processing this directive]